The small GTPase RhoB suppresses cancer in part by limiting cell proliferation. However, the mechanisms it uses to achieve this are poorly understood. Recent studies link RhoB to trafficking of Akt, which through its regulation of glycogen synthase kinase-3 (GSK-3) has an important role in controlling the stability of the c-Myc oncoprotein. c-Myc stabilization may be a root feature of human tumorigenesis as it phenocopies an essential contribution of SV40 small T antigen in human cell transformation. In this study we show that RhoB directs efficient turnover of c-Myc in established or transformed mouse fibroblasts and that the attenuation of RhoB which occurs commonly in human cancer is a sufficient cause to elevate c-Myc levels. Increased levels of c-Myc elicited by RhoB deletion increased the proliferation of nullizygous cells, whereas restoring RhoB in null cells decreased the stability of c-Myc and restrained cell proliferation. Mechanistic analyses indicated that RhoB facilitated nuclear accumulation of GSK-3 and GSK-3-mediated phosphorylation of c-Myc T58, the critical site for ubiquitination and degradation of c-Myc. RhoB deletion restricted nuclear localization of GSK-3, reduced T58 phosphorylation, and stabilized c-Myc. These effects were not associated with changes in phosphorylation or localization of Akt, however, differences were observed in phosphorylation and localization of the GSK-3 regulatory Akt-related kinase, serum-and glucocorticoid-inducible protein kinase (SGK). The ability of RhoB to support GSK-3-dependent turnover of c-Myc offers a mechanism by which RhoB acts to limit the proliferation of neoplastically transformed cells.
Introduction
Rho proteins integrate actin organization with many cellular processes, including cell division. Beyond their diverse roles in normal physiology, Rho proteins also control pathological processes such as cancer (Jaffe and Hall, 2002; Sahai and Marshall, 2002) . The RhoA, RhoB, and RhoC proteins form a closely related subgroup that are B90% identical in amino acid sequence. While all regulate actin stress fiber formation, each has distinct roles in normal physiology and pathology, probably arising from differences in subcellular localization that allow effector interactions to be partitioned (Adamson et al., 1992) . In particular, RhoB differs from RhoA and RhoC in its localization to intracellular endosomes and in its antiproliferative and apoptotic properties (Prendergast, 2001) . Moreover, in contrast with RhoA and RhoC, RhoB is widely attenuated in human cancer (Wang et al., 2003) . While the existing evidence argues that RhoB acts in a distinct manner to restrain cancer and/or cancer progression, the mechanisms through which it acts are obscure.
Recent studies argue that RhoB regulates the intracellular trafficking of key cell signaling molecules. Mellor and colleagues demonstrated initially that RhoB dictates trafficking of the epidermal growth factor receptor (EGFR) (Mellor et al., 1998; Gampel et al., 1999) , acting between late endosomes and multivesicle bodies on the pathway to the lysosome (Wherlock et al., 2004) . More recently, RhoB has been shown to regulate trafficking of the Akt and Src kinases (Adini et al., 2003; Sandilands et al., 2004) . In the case of Akt, support for some regulatory circuit is suggested by the report that RhoB forms a ternary complex with the Rho effector kinase PRK and the pivotal Akt regulatory kinase PDK1 (Flynn et al., 2000) , and by the evidence that Akt downregulates RhoB expression in cancer cells (Jiang et al., 2000) , perhaps reflecting a feedback loop. Given the emerging regulatory connections between RhoB and the Akt pathway, and the important contributions of the Akt pathway to c-Myc regulation (Sears et al., 2000) , we hypothesized that RhoB might limit cell proliferation by influencing the level of c-Myc expression.
c-Myc is essential for cell division and its expression is deregulated or upregulated in virtually all human cancers during tumor progression (Nesbit et al., 1999) . In normal cells, c-Myc is short-lived and tightly regulated to allow fine, rapid changes in its steady-state expression level. Phosphorylation of two critical aminoacid residues dictate the stability of c-Myc. Both sites, T58 and S62, lie within the Myc Box 1 region located in the N-terminal transactivation domain (Lutterbach and Hann, 1994) . Phosphorylation of S62 stabilizes c-Myc whereas subsequent phosphorylation of T58 targets cMyc for ubiquitination and degradation (Sears et al., 2000) . The significance of T58 to c-Myc function in cancer is illustrated in several ways. First, T58 is mutated commonly in human lymphomas and other cancers and in all retroviral v-Myc proteins (Papas and Lautenberger, 1985; Bhatia et al., 1994) . Second, T58 mutations stabilize c-Myc and promote its accumulation in cells, providing a mechanism that could drive cell division and cell tranfsormation (Henriksson et al., 1993; Pulverer et al., 1994; Salghetti et al., 1999) . Lastly, c-Myc stabilization may be a root feature of human tumorigenesis, because it phenocopies the essential contribution of SV40 small T antigen to human cell transformation (Yeh et al., 2004) .
c-Myc is targeted by the Akt/GSK-3 pathway that controls T58 phosphorylation (Sears et al., 2000) . GSK-3 is a well-characterized substrate of Akt but also the Akt-related kinase SGK (Sakoda et al., 2003) . A fraction of active GSK-3 trafficks to the nucleus where it colocalizes with c-Myc, consistent with its role in phosphorylating c-Myc and regulating its stability (Gregory et al., 2003) . Once phosphorylated at T58 by GSK3, c-Myc is recognized by Fbw7, a component of the SCF(Fbw7) ubiquitin ligase that is responsible for directing proteasome-mediated degradation (Welcker et al., 2004a, b; Yada et al., 2004) . Upstream of c-Myc there remains a major gap in knowledge about the mechanisms that support accumulation of active GSK-3 in the nucleus. In this study, we show that RhoB facilitates GSK-3-dependent turnover of c-Myc by supporting efficient nuclear accumulation of active GSK-3. These results suggest that RhoB may act to limit cell proliferation in part by promoting GSK-3-dependent turnover of c-Myc protein. Further, they suggest that RhoB attenuation may be selected for commonly in human cancers as a mechanism to promote c-Myc stabilization and thereby c-Mycmediated cell proliferation.
Results
Loss of rhoB enhances c-Myc protein stability and cell proliferation RhoB can modulate trafficking of Akt (Adini et al., 2003) , which through its regulation of GSK-3 has an important role in controlling c-Myc stability (Sears et al., 2000) . Previous studies have shown RhoB to limit the proliferation of transformed cells Liu et al., 2001a, b) . Therefore, we compared the effects of rhoB deletion on the expression and kinetics of c-Myc turnover in E1A þ Ras transformed mouse embryonic fibroblasts (ER MEFs), a well-characterized model in our laboratory. Because rhoB is haplosufficient to limit proliferation in this model we compared ER þ /-MEFs and ER -/-MEFs to control for the neo cassette used in the null cells for gene replacement. We observed that steady-state levels of c-Myc protein were elevated in ER -/-cells ( Figure 1a) . To confirm the effects of rhoB deletion in another cell system, we compared the steady-state levels of c-Myc in spontaneously immortalized MEFs that were established on a 3T3 passaging schedule (3T3 cells). As in ER -/-MEFs, c-Myc was elevated similarly in 3T3 -/-cells (data not shown). To determine whether the effects in each system was associated with increased protein stability, we exposed cells to short-term treatment with 10 mg/ml of the translation inhibitor cycloheximide (CHX) and examined steady-state c-Myc protein levels by Western analysis at various times afterward. In both cell systems, the kinetics of c-Myc turnover were markedly decreased in ER -/-MEFs (Figure 1b and c) and 3T3 -/-cells (data not shown). cMyc elevation would be expected to elevate the rate of cellular proliferation, therefore, we asked whether cells lacking RhoB proliferated more rapidly. Both ER -/-MEFs and 3T3 -/-cells exhibited more rapid proliferation compared to control cells (Figure 1d and e). In summary, we conclude that RhoB restrains c-Myc expression and c-Myc-dependent cell proliferation by facilitating efficient turnover of c-Myc protein.
Restoring expression of RhoB in null cells destabilizes c-Myc and limits cell growth To rule out the possibility that nonspecific compensating alterations were responsible for c-Myc stabilization in our cell models, we restored RhoB into null cells to confirm the expectation that this would be sufficient to re-regulate c-Myc turnover. Briefly, retroviral vectors were used to introduce an epitope-tagged wild-type RhoB protein (RhoB-WT) or an engineered exclusively geranylgeranylated derivative (RhoB-GG) elicited by farnesyl transferase inhibitors that is known to be sufficient to mediate growth inhibition in ER MEFs (Du et al., 1999) . Consistent with our expectations, ectopic expression of RhoB-WT or RhoB-GG in null cells decreased steady-state levels of c-Myc (Figure 2a ) in a manner that was associated with increased c-Myc turnover (Figure 2b) . Additionally, reduced c-Myc levels were correlated in turn with reduced cell proliferation (Figure 2c ). Taken together, these observations confirmed that the relative accumulation of c-Myc in null cells was indeed directly due to the absence of RhoB.
RhoB modulates GSK-3-mediated phosphorylation and ubiquitylation of c-Myc Having found that RhoB loss promoted c-Myc stability, we went on to compare the effects of RhoB loss on the machinery that is responsible for controlling c-Myc turnover. A central regulator of c-Myc turnover is Ras (Sears et al., 1999) . Ras acts through two opposing pathways, the Raf-MEK-ERK pathway that directly targets c-Myc, and the PI3K-Akt pathway that indirectly targets c-Myc by attenuating the activity of its regulatory kinase GSK-3b (Sears et al., 2000) . The targets of ERK and GSK-3b phosphorylation in c-Myc are S62 and T58, respectively, each of which are located in the conserved Myc Box 1 region of N-terminal transactivation domain. In particular, GSK-3b-mediated phosphorylation of T58 is critical for ubiquitination and subsequent proteasome-dependent degradation of c-Myc (Sears et al., 2000) .
In support of the observation that RhoB facilitates cMyc turnover, we observed reduced steady-state levels of T58 phosphorylation in ER -/-MEFs, relative to control ER þ /-MEFs ( Figure 3a) . Furthermore, we observed a relative reduction in ubiquitinated c-Myc and in phospho-T58 c-Myc levels in ER -/-MEFs following proteasome inhibition, as compared to ER þ /-MEFs (Figure 3b and c). These results confirmed the expectation that reduced T58 phosphorylation leads to reduced ubiquitination and thereby reduced degradation of c-Myc. One question was whether GSK-3b was in fact responsible for phosphorylating c-Myc T58 in this system. To address this question, we treated ER þ /-MEFs with LiCl, a potent inhibitor of GSK-3 kinase activity, or with KCl as a negative control. LiCl abolished phosphorylation of cMyc T58 in ER þ /-MEFs (Figure 3d ), confirming that T58 was indeed phosphorylated by GSK-3b. Together, the results argued that the reduction in T58 phosphorylation caused by RhoB loss was due to a reduction in the activity or nuclear localization of GSK-3b. In either case, they supported the interpretation that RhoB facilitates c-Myc turnover by supporting GSK-3-mediated T58 phosphorylation, an event that is crucial to direct ubiquitination and efficient degradation of c-Myc.
RhoB deletion alters the status of GSK-3b and SGK Through their ability to phosphorylate and inactivate GSK-3b, the Akt kinases can act upstream to modulate the turnover of c-Myc (Sears, 2004) . Various studies have suggested a link between RhoB and Akt based on the ability of RhoB to (i) form a ternary complex with PRK and PDK1 in HeLa cells (Flynn et al., 2000) ; (ii) suppress the kinase activity of Akt in human cancer cells (Chen et al., 2000; , and (iii) control the nuclear trafficking of Akt in murine endothelial cells (Adini et al., 2003) . Western analysis was performed to examine the status of various elements of the Akt pathway in ER MEFs. No difference was observed in the level or activation status of PRK and PDK1, as determined by appropriate pan or phosphospecific antibodies (Figure 4) . While ER -/-MEFs exhibited a steady-state increase in the level of Akt and decrease in the level of GSK-3b, the phosphorylation of Akt and GSK-3b was not changed compared to ER þ /-MEFs (Figure 4) . The ratio of phospho-S9 GSK-3b to total GSK-3b indicates that the activity of GSK-3b is (Figure 4) . For this reason, we investigated the effect of RhoB loss on the Akt-related kinase serumand glucocorticoid-regulated kinase (SGK), which phosphorylates and downregulates GSK-3b in the same manner as Akt (Sakoda et al., 2003) . ER -/-MEFs displayed an increase in levels of active phospho-T256 SGK (Figure 4) . Thus, SGK could be responsible for the high proportion of phospho-GSK-3b present in the RhoB null cells. Together, the results argued that RhoB deletion decreases the phosphorylation of c-Myc at T58 by attenuating the activity of GSK-3b, possibly through SGK-mediated phosphorylation.
Altered localization of GSK-3b and SGK in cells lacking RhoB
We next evaluated the possibility that RhoB influenced the nuclear accumulation of Akt, SGK or GSK-3b. The regulatory linkage between GSK-3 and c-Myc has been strengthened recently with evidence that GSK-3b binds directly to c-Myc and colocalizes with it in the nucleus (Gregory et al., 2003) . In ER MEFs, indirect immunofluorescence analysis showed that GSK-3b was localized in both the cytoplasm and nucleus in ER7 cells (Figure 5a ), organized into a punctate pattern in the nucleus that was consistent with that described previously (Gregory et al., 2003) . In contrast, GSK-3b was largely excluded from the nucleus in ER -/-MEFs, where instead cytoplasmic localization was predominant (Figure 5a ). This observation was important, because it suggested that RhoB was essential to facilitate efficient accumulation of GSK-3b in the cell nucleus where cMyc resides, providing another mechanism to explain how RhoB loss could reduce the efficiency of T58 phosphorylation. Since we had observed that RhoB loss was associated with elevated phosphorylation of SGK, we also investigated the subcellular localization of SGK in ER MEFs. SGK localized to the nucleus of ER þ /-MEFs ( Figure 5b ). Staining appeared to be concentrated at the outer margins of the nucleus, reminiscent of a pattern that has been reported for nuclear Akt (Adini et al., 2003) . Notably, SGK localized to the cytosol as well as the nucleus in ER -/-MEFs (Figure 5b ). In these cells, margination of SGK in the nucleus was not apparent. Similar experiments to examine the subcellular localization of Akt did not reveal any apparent effects of RhoB loss (data not shown).
To confirm that the effect of RhoB on the nuclear localization of GSK-3b was direct, we compared the localization of GSK-3b in null cells where RhoB-WT or RhoB-GG were ectopically expressed by retroviral infection. Nuclear accumulation of GSK-3b was apparent in cells where RhoB-WT or RhoB-GG was expressed, but not in the vector control cells (Figure 6 ), the latter of which phenocopied the parental null cells. 
RhoB facilitates c-Myc turnover M Huang et al
To confirm these cell biological observations, we fractionated cell extracts and compared the expression of GSK-3b and SGK in cytosolic and nuclear extracts by Western blotting. The normalized level of GSK3b in the nucleus was relatively reduced in ER -/-MEFs (Figure 5c and d), whereas as the normalized level of SGK in the cytosol was relatively increased in ER -/-cells (Figure 5c, e) . Taken together, we interpreted the results to mean that RhoB supported GSK-3b-mediated turnover of c-Myc by facilitating the nuclear accumulation of GSK-3b, the latter of which occurred by a mechanism that was coordinated with alterations in SGK activity and localization.
Discussion
Our results suggest a mechanism by which RhoB limits cell proliferation, addressing gaps in knowledge about how RhoB inhibits the growth of transformed cells and how RhoB downregulation in human cancers may facilitate malignant progression (Adnane et al., 2002; Status of the Akt/SGK pathway in cells lacking RhoB. ER MEF lysates were prepared and analysed by Western blotting using the antibodies indicated to detect steady-state expression levels and phosphorylation/activation status. Mazieres et al., 2004; Wang et al., 2004) . Using a knockout mouse model system, we found that RhoB loss increased the stability of c-Myc in a manner associated with reduced efficiency of nuclear accumuation and activity of GSK-3 and with reduced phosphorylation of c-Myc T58, an event that is essential for efficient degradation of c-Myc (Salghetti et al., 1999; Sears et al., 2000; Welcker et al., 2004b; Yada et al., 2004; Yeh et al., 2004) . Critical phosphorylation events regulating c-Myc protein stability occur in the amino terminal domain termed Box1 (Flinn et al., 1998) . These events involve the hierarchical phosphorylation of S62 and T58 by ERK1/2 MAPK and GSK3, respectively (Lutterbach and Hann, 1994) . Although it is reported that these kinases mediate phosphorylation events at these residues, other reports indicate that MEKK1 and JNK kinases can also contribute to the regulation of cMyc stability through a novel domain other than Box1 or Box2 (Alarcon-Vargas et al., 2002; Alarcon-Vargas and Ronai, 2004) . On the basis of the T58-based mechanism of action, there is reason to think that the role of RhoB may be relevant to both c-Myc-mediated cell proliferation and to cancer progression. First, T58 is mutated in all retroviral v-Myc proteins and in a variety of cancer-associated Myc proteins, resulting in elevated protein stability and oncogenic capacity (Papas and Lautenberger, 1985; Bhatia et al., 1993 Bhatia et al., , 1994 Pulverer et al., 1994; Salghetti et al., 1999) . Second, the Fbw7 subunit of the ubiquitin ligase that recognizes T58-phosphorylated c-Myc is a tumor suppressor (Tetzlaff Restoring expression of RhoB in null cells enhances nuclear localization of GSK-3b. Effect of RhoB on GSK-3b localization in ER MEF À/À cells was performed by indirect immunofluorescence analysis. Cells that infected with empty vector of MSCVpac, MSCV-WT or MSCV-GG were seeded overnight onto coverslips and then fixed and stained with anti-GSK-3b before processing for fluorescence microscopy with a deconvolution software. Cell nuclei were visualized by co-staining with DAPI.
et al., 2004; Welcker et al., 2004b) . Lastly, stabilization of c-Myc may be critical to tumorigenesis, based on evidence that expression of c-Myc T58 mutant proteins can phenocopy the requirement for SV40 small T antigen in human cell transformation (Yeh et al., 2004) . Thus, the ability to modulate T58 phosphorylation of c-Myc offers a potentially important mechanism through which RhoB could limit the proliferation of cancer cells, acting as a negative modifier gene or an antiprogression gene. The critical regulator of T58 phosphorylation in cMyc is the growth regulatory kinase GSK-3b (Sears et al., 2000; Welcker et al., 2004b; Yada et al., 2004; Yeh et al., 2004) . Recent report also showed that GSK3 and Fbw7 coordinately regulates another oncogenic factor, c-Jun (Wei et al., 2005) . We found that RhoB loss attenuated c-Myc turnover in a manner associated with GSK-3-dependent phosphorylation of T58. RhoB deletion led to a marked inactivation of GSK-3b but also to a reduction in the efficiency of GSK-3 nuclear localization. The observations support an interpretation whereby RhoB attenuation limits the activity of GSK-3b and its ability to access c-Myc in the nucleus. While the precise mechanistic linkage between RhoB and GSK-3b suggested by our findings has yet to be elucidated, a foundation for invoking a connection through Akt/ SGK connection is tenable, based on the ability of RhoB loss to influence SGK activation status and/or subcellular localization, as well as several reports suggesting that RhoB can modulate Akt trafficking and/or signaling (Flynn et al., 2000; Jiang et al., 2000; Adini et al., 2003) . SGK is a serine/threonine protein kinase with a catalytic domain that is highly homologous to Akt and that phosphorylates and inactivates GSK3 like Akt (Sakoda et al., 2003) . Similar to Akt, SGK shuttles between the nucleus and cytoplasm in synchrony with the cell cycle, residing in the nucleus of cells that are stimulated with growth factors and in the cytosol in cells exposed to environmental stress (Firestone et al., 2003) . In our study, RhoB deletion led to an increase of phosphorylated cytosolic SGK, which could explain the observed increase in phosphorylated GSK-3b that was relatively excluded from the nucleus. Figure 7 summarizes a model for how RhoB faciliates c-Myc turnover (adapted from Sears et al., 2000) . In the model, RhoB supports efficient nuclear accumulation of GSK-3 and affects the Akt/SGK-based signaling pathway that regulates GSK-3 activity. This 'signal trafficking' mechanism is proposed to be distinct but integrated with the signaling process that is controlled by Akt/ SGK. Loss of RhoB affects signal trafficking and process in the model, thereby limiting efficient nuclear accumulation of active GSK-3 and its efficient access to c-Myc. While fuller molecular understanding is necessary, this model suggests a framework for evaluating how RhoB may negatively modify cancer cell proliferation and how RhoB loss may promote cancer progression. At a broader level, the model illustrates how c-Myc expression is modified by signaling trafficking processes that could act to modify the efficiency of signaling pathways targeting c-Myc, perhaps important in stress settings and cancer. In future work, it will be important to gain insights into the proximal mechanisms of RhoB on GSK-3-mediated turnover of c-Myc, and to gauge the pathophysiological impact of the pathway in epithelial cancers where it appears to be attenuated quite often.
Materials and methods

Cell culture
The generation and culture of mouse embryonic fibroblasts (MEFs) transformed by adenovirus E1A and mutant H-Ras has been described previously . E1A þ Rastransformed MEFs that are heterozygous or nullizygous for RhoB are termed ER þ /-or ER -/-cells, respectively. Wildtype homozygous MEFs exhibit similar biological properties to heterozygous MEFs, the latter of which were matched to nullizygous MEFs to control for the presence of the neomycin resistance cassette employed for rhoB gene replacement (Liu et al., 2001b) . Wild-type homozygous and RhoB deletion in spontaneously immortalized MEFs were established on a 3T3 passaging schedule and termed 3T3 þ / þ and 3T3 -/-cells. The cells were maintained in Dulbecco's modified Eagle medium (DMEM) (Cellgro, Herndon, VA, USA) containing 10% fetal bovine serum (Hyclone, Logan, UT, USA). Anchorage-dependent cell growth was measured by a standard sulforhodamine B assay (Skehan et al., 1990) Signal trafficking by RhoB. In the model, RhoB facilitates efficient trafficking of GSK-3 in concert with its regulation by Akt or SGK. The signal trafficking mechanism is distinct but coordinated with the signaling mechanism (i.e. GSK-3 phosphorylation). Loss of RhoB limits c-Myc turnover not only by influencing signaling to GSK-3, but also by abolishing a trafficking process that acts to facilitate efficient nuclear accumulation of GSK-3. The model is adapted from Sears et al. (2000) .
Virus production and infection
Ectopically expression of wild-type RhoB (RhoB-WT) or the geranylgeranylated isoform of RhoB (RhoB-GG) in RhoB null cells were generated by infection with recombinant retroviruses. Generation of recombinant retroviruses has been described previously that a hemagglutinin antigen epitope (HA)-tagged RhoB-WT cDNA or RhoB-GG cDNA was subcloned into the replication-incompetent retroviral vector MSCVpac, which includes a puromycin selection marker (Zeng et al., 2003) . Recombinant MSCVpac viruses were packaged by standard methods in Phoenix cells. After infection, cells were passaged into DMEM media containing 1-2 mg/ml puromycin and drug-resistant cell populations were pooled for analysis.
Western analysis
Unless otherwise noted in the figure legend, cells were harvested by scraping into hot 1 Â SDS sample buffer at a cell-to-volume ratio of 2.5 Â 10 6 cells/ml. Protein concentrations were normalized using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA), according to the manufacturer's instructions. Equal protein for each sample (typically 50 mg/ lane) was separated by SDS-PAGE and blotted onto Immobilon-NC membrane (Millipore, Billerica, MA, USA). Blots were incubated with primary antibodies as recommended by the vendor and were detected with HRP-conjugated secondary antibodies using the ECL reagents from PIERCE, according to the manufacturer's instructions. Quantitation analysis of SDS-PAGE images was carried out using Image Quant software (Molecular Dynamics, Inc., Sunnyvale, CA, USA). Primary antibodies to the following antigens were used: RhoB (Bethyl Laboratories, Montgomery, TX, USA); N262 cMyc, C33 c-Myc, phospho-SGK (T256) and actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA); phospho-c-Myc (T58/ S62), PDK1, phospho-PDK1 (S241), SGK, Pin1, Akt, phospho-Akt (T308), GSK3b, and phospho-GSK3b (S9) (Cell Signaling Technology, Beverly, MA, USA); ubiquitin (Zymed, South San Francisco, CA, USA); PRK1 and PP2A catalytic subunit (BD Transduction Laboratories, San Jose, CA, USA).
Cell fractionation
Cells were washed with PBS and scraped into hypotonic lysis buffer (10 mM Tris, pH 7.4, 1.5 mM MgCl 2 , 10mM KCl, 0.5 mM DTT, protease inhibitor cocktail (Calbiochem)), and then incubated on ice for 10 min. The lysate was Dounce homogenized (40 strokes) with a tight-fitting pestle. The nuclear fraction was obtained by centrifuging the homogenate at 3300 g for 15 min. After removing the supernatant (cytoplasmic extract), the pellet (nuclear fraction) was layered over 30% sucrose (0.88 M) in hypotonic buffer and was centrifuged twice at 800 g. Proteins were quantitated and 50 mg was analysed by SDS-PAGE and Western blotting.
Ubiquitin detection
Cells were washed with cold PBS and lysed with RIPA buffer (cell-to-volume ratio of 1 Â 10 6 cells/ml) containing protease and phosphatase inhibitors including 5 mM of the deubiquitinase inhibitor N-ethylmaleimide (NEM; Sigma, St Louis, MO, USA). Ubiquitinated proteins were immunoprecipitated from cell lysates with antiubiquitin antibody (Zymed) and collected on protein G-agarose beads. Immunoprecipitates were washed once with low-stringency buffer containing PBS/0.1% NP-40 plus the inhibitors used above. Immunoprecipitated proteins were then fractionated on 10% SDS-PAGE gels, blotted onto immobilon-NC membranes, and detected with indicated c-Myc antibodies.
Indirect immunofluorescence
Cells were seeded overnight on coverslips in 12-well dishes in DMEM containing 10% FBS. The next day cells were rinsed with PBS, fixed 10 min in 4% paraformaldehyde, and permeabilized 5 min with 0.2% Triton X-100 in PBS. After blocking by incubation for 30 min in 1% PBS/bovine serum albumin, cells were incubated 1 h with the indicated primary antibody at a dilution of 10 mg/ml. Cells were then incubated for 30 min with the Cyt3-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Lastly, to visualize nuclei, cells were stained 5 min with 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma, St Louis, MO, USA). After washing with PBS, the coverslips were mounted on slides with Fluoromount G (Southern Biotechnology Associates, Birmingham, LA, USA) for examination by fluorescence microscopy.
